215 related articles for article (PubMed ID: 34518311)
41. Novel Insights of Anti-EGFR Therapy in HNSCC: Combined with Immunotherapy or Not?
Dong L; Wang Y; Yao X; Ren Y; Zhou X
Curr Oncol Rep; 2023 Feb; 25(2):93-105. PubMed ID: 36585960
[TBL] [Abstract][Full Text] [Related]
42. Up-regulation of NK cell function against head and neck cancer in response to ss-isRNA requires TLR7.
Pries R; Wulff S; Kesselring R; Börngen K; Xie L; Wollenberg B
Int J Oncol; 2008 Nov; 33(5):993-1000. PubMed ID: 18949362
[TBL] [Abstract][Full Text] [Related]
43. Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias.
Pietra G; Vitale C; Pende D; Bertaina A; Moretta F; Falco M; Vacca P; Montaldo E; Cantoni C; Mingari MC; Moretta A; Locatelli F; Moretta L
Cancer Immunol Immunother; 2016 Apr; 65(4):465-76. PubMed ID: 26289090
[TBL] [Abstract][Full Text] [Related]
44. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells.
McKenna HJ; Stocking KL; Miller RE; Brasel K; De Smedt T; Maraskovsky E; Maliszewski CR; Lynch DH; Smith J; Pulendran B; Roux ER; Teepe M; Lyman SD; Peschon JJ
Blood; 2000 Jun; 95(11):3489-97. PubMed ID: 10828034
[TBL] [Abstract][Full Text] [Related]
45. Flt3 ligand delivered in a pluronic formulation prolongs the survival of mice with orthotopic pancreatic adenocarcinoma.
Ashour AE; Turnquist HR; Burns N; Wang X; Lin X; Tremayne J; Hollingsworth MA; Blonder JM; Rosenthal GJ; Talmadge JE; Solheim JC
Cancer Biother Radiopharm; 2007 Apr; 22(2):235-8. PubMed ID: 17600470
[TBL] [Abstract][Full Text] [Related]
46. Association of CD47 with natural killer cell-mediated cytotoxicity of head-and-neck squamous cell carcinoma lines.
Kim MJ; Lee JC; Lee JJ; Kim S; Lee SG; Park SW; Sung MW; Heo DS
Tumour Biol; 2008; 29(1):28-34. PubMed ID: 18497546
[TBL] [Abstract][Full Text] [Related]
47. TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells.
Stephenson RM; Lim CM; Matthews M; Dietsch G; Hershberg R; Ferris RL
Cancer Immunol Immunother; 2013 Aug; 62(8):1347-57. PubMed ID: 23685782
[TBL] [Abstract][Full Text] [Related]
48. Combined use of NK cells and radiotherapy in the treatment of solid tumors.
Zheng W; Ling S; Cao Y; Shao C; Sun X
Front Immunol; 2023; 14():1306534. PubMed ID: 38264648
[TBL] [Abstract][Full Text] [Related]
49. Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy.
Shaver KA; Croom-Perez TJ; Copik AJ
Front Immunol; 2021; 12():679117. PubMed ID: 33995422
[TBL] [Abstract][Full Text] [Related]
50. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.
Gaggero S; Witt K; Carlsten M; Mitra S
Front Immunol; 2020; 11():621225. PubMed ID: 33584718
[TBL] [Abstract][Full Text] [Related]
51. Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma.
Okuyama K; Naruse T; Yanamoto S
J Exp Clin Cancer Res; 2023 May; 42(1):114. PubMed ID: 37143088
[TBL] [Abstract][Full Text] [Related]
52. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J
J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749
[TBL] [Abstract][Full Text] [Related]
53. Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.
André P; Denis C; Soulas C; Bourbon-Caillet C; Lopez J; Arnoux T; Bléry M; Bonnafous C; Gauthier L; Morel A; Rossi B; Remark R; Breso V; Bonnet E; Habif G; Guia S; Lalanne AI; Hoffmann C; Lantz O; Fayette J; Boyer-Chammard A; Zerbib R; Dodion P; Ghadially H; Jure-Kunkel M; Morel Y; Herbst R; Narni-Mancinelli E; Cohen RB; Vivier E
Cell; 2018 Dec; 175(7):1731-1743.e13. PubMed ID: 30503213
[TBL] [Abstract][Full Text] [Related]
54. Flt3 ligand treatment modulates parasitemia during infection with rodent malaria parasites via MyD88- and IFN-γ-dependent mechanisms.
Tamura T; Akbari M; Kimura K; Kimura D; Yui K
Parasite Immunol; 2014 Feb; 36(2):87-99. PubMed ID: 24400637
[TBL] [Abstract][Full Text] [Related]
55. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
56. CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation.
Reyes RM; Zhang C; Deng Y; Ji N; Mukherjee N; Padron AS; Clark CA; Svatek RS; Curiel TJ
Oncoimmunology; 2021; 10(1):2006529. PubMed ID: 34858732
[TBL] [Abstract][Full Text] [Related]
57. Combination of radiotherapy with the immunocytokine L19-IL2: Additive effect in a NK cell dependent tumour model.
Rekers NH; Zegers CM; Yaromina A; Lieuwes NG; Biemans R; Senden-Gijsbers BL; Losen M; Van Limbergen EJ; Germeraad WT; Neri D; Dubois L; Lambin P
Radiother Oncol; 2015 Sep; 116(3):438-42. PubMed ID: 26138057
[TBL] [Abstract][Full Text] [Related]
58. NK Cell-Dependent Antibody-Mediated Immunotherapy Is Improved In Vitro and In Vivo When Combined with Agonists for Toll-like Receptor 2 in Head and Neck Cancer Models.
Gruijs M; Ganzevles SH; Stigter-van Walsum M; van der Mast R; van Ostaijen-Ten Dam MM; Tuk CW; Schilham MW; Leemans CR; Brakenhoff RH; van Egmond M; van de Ven R; Bakema JE
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681717
[TBL] [Abstract][Full Text] [Related]
59. The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab
Baysal H; De Pauw I; Zaryouh H; Peeters M; Vermorken JB; Lardon F; De Waele J; Wouters A
Front Immunol; 2021; 12():737311. PubMed ID: 34557197
[TBL] [Abstract][Full Text] [Related]
60. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]